Laboratory Corp of America Holdings (LH):医療機器:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C7042)
◆英語タイトル:Laboratory Corp of America Holdings (LH) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA904C7042
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年10月
◆ページ数:151
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥26,250見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥52,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥78,750見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Laboratory Corp of America Holdings (LabCorp) is a provider of clinical laboratory services and end-to-end drug development support. It focuses on the development and commercialization of a wide range of diagnostic technologies and testing services. The company offers clinical diagnostics laboratory services such as core testing, genomic and esoteric testing. Its services include general and specialty laboratory testing, ambulatory monitoring services, bone marrow and human leukocyte antigen (HLA) testing, clinical trials services, drug testing services, DNA identification services, forensic identity services, insurance health plan services, paternity testing services, patient services, personalized medicine and hospital services. It also offers drug development services through Covance. It offers its services to managed care organizations, physicians, hospitals, government agencies and biotechnology and pharmaceutical companies through a network of primary laboratories and patient service centers. The company has operations across the US, Columbia, Belgium, Puerto Rico, Japan, China, Singapore, the UK and three Canadian provinces. LabCorp is headquartered in Burlington, North Carolina, the US.

Laboratory Corp of America Holdings (LH) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 7
Laboratory Corp of America Holdings, Medical Equipment, Deals By Year, 2012 to YTD 2018 8
Laboratory Corp of America Holdings, Medical Equipment Deals By Type, 2012 to YTD 2018 9
Laboratory Corp of America Holdings, Medical Equipment, Deals By Region, 2012 to YTD 2018 10
Laboratory Corp of America Holdings, Medical Equipment, Deals By Market, 2012 to YTD 2018 11
Laboratory Corp of America Holdings, Medical Equipment, Deals Summary, 2012 to YTD 2018 12
Laboratory Corp of America Holdings, Medical Equipment, Deal Details 17
Asset Purchase 17
Sequenom Acquires Noninvasive Prenatal Testing Intellectual Property from Isis Innovation for USD14.5 Million 17
Pharma Tech Solutions Acquires Genstrip From Shasta Technologies 19
Sequenom Acquires Molecular Diagnostic Application Patents From Helicos BioSciences For US$1.3 Million 20
Venture Financing 21
Orig3n Raises Funds through Initial Closing of Series B Financing 21
OmniSeq Plans to Raise Funds through Series B Financing 23
Sera Prognostics Raises USD40 Million in Series C Financing 24
Seventh Sense Biosystems Raises USD10 Million in Series C Financing 25
Ativa Medical Raises USD15 Million in Series B Financing 27
Vivify Health Raises Funds in Series B Venture Financing 29
Seventh Sense Biosystems Raises USD16 Million in Series B Financing 30
Flatiron Health Raises US$130 Million In Series B Financing 32
Flatiron Health Raises US$8 Million In Series A Financing 34
Private Equity 36
Decision Diagnostics Plans to Raise USD4.7 Million in Financing 36
Partnerships 37
LabCorp Enters into Licensing Agreement with MDNA Life Sciences 37
Sequenom Enters into Licensing Agreement with Mayo Medical Labs 38
Sequenom Enters Into Licensing Agreement With Laboratoire Cerba For MaterniT21 PLUS 39
Ingenuity Systems Enters Into Licensing Agreement With LabCorp For Clinical Content And Applications 41
Sequella Enters Into Licensing Agreement With LabCorp For B-Smart Technology 42
LipoScience Enters Into Licensing Agreement With Cleveland Clinic 43
LabCorp Enters Into Licensing Agreement With OPKO Health For Alzheimer’s Diagnostic Technology 44
Covance Enters into Strategic Technology Agreement with GlaxoSmithKline 45
MC10 Enters into Partnership with LabCorp 46
OmniSeq Enters into Distribution Agreement with Laboratory Corp of America 47
Sera Prognostics Enters into Agreement with LabCorp 48
Interpace Diagnostics Extends Agreement with LabCorp 49
Sequenom enters into an Agreement with University of California 50
Sysmex Enters into Co-Development Agreement with LabCorp 51
Cypher Genomics Enters into Agreement with Sequenom to Develop Next Generation Noninvasive Prenatal Tests 52
Gamma-Dynacare Medical Labs Enters Into Agreement With OSR Medical 53
Covance And Pathoquest Enter Into Agreement For Sequencing-Based Biosafety Assessments 54
Enzo Clinical Labs And Sequenom Enter Into Agreement To Market MaterniT21 Plus 55
Sequenom And CombiMatrix Enter Into Agreement To Market Chromosomal Microarray Analysis For Prenatal Testing 56
CombiMatrix Expands Co-Marketing Agreement With Pathology For Prenatal Tests 57
CombiMatrix Enters Into Co-Marketing Agreement With Pathology For Prenatal Tests 58
Mitomics Enters Into Co-Marketing Agreement With LabCorp For Prostate Core Mitomic Test 59
XDx Enters Into Agreement With LabCorp To Develop Lupus Flare Predictor Test 60
Equity Offering 61
MC10 Raises Funds through Private Placement of Shares 61
LipoScience Completes IPO For US$52 Million 62
Sequenom Completes Public Offering Of Common Stock For US$62 Million 64
Debt Offering 66
LabCorp Raises USD600 Million in Public Offering of 3.6% Notes Due 2027 66
LabCorp Raises USD600 Million in Public Offering of 3.25% Notes Due 2024 68
LabCorp Raises USD500 Million in Public Offering of 2.625% Notes Due 2020 70
LabCorp Raises USD1 Billion in Public Offering of 3.6% Notes Due 2025 72
LabCorp Raises USD900 Million in Public Offering of 4.7% Notes Due 2045 74
LabCorp Raises USD500 Million in Public Offering of 3.2% Notes Due 2022 76
LabCorp Completes Public Offering Of Notes Due 2018 For US$400 Million 78
LabCorp Completes Public Offering Of Notes Due 2023 For US$300 Million 80
Sequenom Completes Private Placement Of Notes Due 2017 For US$130 Million 82
LabCorp Completes Public Offering Of Senior Notes Due 2017 For US$500 Million 83
LabCorp Completes Public Offering Of Senior Notes Due 2022 For US$500 Million 85
Asset Transactions 87
Sequenom Plans to Sell Clinical Genomic Lab in North Carolina 87
Marken Acquires European Kit Building Operation Facility From LabCorp 88
Acquisition 89
Eurofins Acquires Covance from LabCorp 89
LabCorp Acquires Sciformix 91
LabCorp Acquires Pathology Associates Medical Labs from Providence Health & Services and Catholic Health Initiatives 92
LabCorp Acquires ClearPath Diagnostics from Shore Capital Partners 94
LabCorp Acquires Sequenom 95
LabCorp Acquires Covance for USD6.1 Billion 97
LabCorp Acquires Bode Technology from SolutionPoint 99
LabCorp Acquires LipoScience for USD85.3 Million 100
Agena Bioscience Completes Acquisition of Sequenom Bioscience for USD31.8 Million 102
Gamma-Dynacare Medical Labs Acquires Controlling Interest In Impact Genetics 103
LabCorp Acquires Minority Stake In SynapDx For US$2 Million 104
LabCorp Completes Acquisition Of Medtox Scientific For US$241 Million 105
Bode Technology Group Acquires Provider Of DNA Analysis Testing Services, Chromosomal Labs 107
Laboratory Corp of America Holdings – Key Competitors 108
Laboratory Corp of America Holdings – Key Employees 109
Laboratory Corp of America Holdings – Locations And Subsidiaries 110
Head Office 110
Other Locations & Subsidiaries 110
Recent Developments 115
Strategy And Business Planning 115
Jun 01, 2018: LabCorp and Unilabs Collaborate to Expand Global Reach of Precision Medicine Capabilities to Serve Patients, Physicians and Pharma 115
Jun 14, 2017: Covance Opens State-of-the-Art Laboratory for Companion Diagnostics 116
Apr 21, 2017: Covance to Expand Large-Molecule Development Capabilities in the UK 117
Financial Announcements 118
Jul 25, 2018: LabCorp Announces 2018 Second Quarter Results and Updates 2018 Guidance 118
Apr 25, 2018: LabCorp Announces Strong 2018 First Quarter Results and Updates 2018 Guidance 120
Feb 06, 2018: LabCorp Reports Net Revenue Of $2.70 Billion In The Fourth Quarter 2017 123
Oct 25, 2017: LabCorp Announces Record Third Quarter Results and Increases 2017 Guidance 126
Jul 26, 2017: LabCorp Announces Record Results in the Second Quarter of 2017 and Increases 2017 Guidance 128
Apr 25, 2017: Laboratory Corporation of America Holdings Announces 2017 First Quarter Results and Updates 2017 Guidance 131
Feb 16, 2017: Laboratory Corporation of America Holdings Announces Record 2016 Fourth Quarter and Full Year Results and Provides 2017 Guidance 133
Corporate Communications 136
Jul 12, 2018: Robert E. Mittelstaedt, Jr. to Retire from LabCorp Board of Directors and Current Board Member Adam H. Schechter to Assume Role of Lead Independent Director in 2019 136
Nov 13, 2017: LabCorp Receives 2017 Partnership Award from Be The Match 137
Aug 24, 2017: LabCorp Names Nationally Recognized Health-Policy Expert Dr. Brian Caveney As Enterprise-Wide Chief Medical Officer 138
Jul 18, 2017: LabCorp’s William Hanlon Appointed to Governing Committee of the National Evaluation System for health Technology Coordinating Center 139
Mar 29, 2017: LabCorp Promotes Executive Gary Huff to CEO of LabCorp Diagnostics, One of the Company’s Two Primary Business Segments 140
Legal and Regulatory 141
Jun 15, 2017: Oxford Immunotec Announces Favorable Claim Construction Ruling in Patent Infringement Litigation 141
Product News 142
Nov 16, 2017: Cority Enhances Clinical Testing Solution with LabCorp Interface 142
Sep 14, 2017: LabCorp Presents Nine Studies, Including Novel Research on Improving Genetic Counseling Quality, at the National Society of Genetic Counselors Annual Conference 143
Apr 28, 2017: LabCorp to Exclusively Offer the M3 Checklist, a Multi-Condition Mental Health Screening Tool 144
Other Significant Developments 146
May 25, 2018: LabCorp to Become a Preferred National Laboratory for Aetna 146
May 01, 2018: LabCorp Announces Collaboration with The Recovery Platform to Assist Physicians Treating Patients with Opioid Dependency 147
Sep 25, 2017: LabCorp Objects to Proposed PAMA 2018 Medicare Payment Rates for Clinical Laboratory Tests; Calls for Delay in Implementation to Avoid Significant Harm to Medicare Beneficiaries 148
Jul 11, 2017: LabCorp and Novant Health Extend Laboratory Services Agreement 149
Jun 28, 2017: Walgreens and LabCorp Collaborate to Bring Patient Service Centers for Laboratory Testing to Select Walgreens Stores 150
Appendix 151
Methodology 151
About GlobalData 151
Contact Us 151
Disclaimer 151

List of Tables
Laboratory Corp of America Holdings, Medical Equipment, Key Facts, 2017 2
Laboratory Corp of America Holdings, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
Laboratory Corp of America Holdings, Medical Equipment, Deals By Year, 2012 to YTD 2018 8
Laboratory Corp of America Holdings, Medical Equipment Deals By Type, 2012 to YTD 2018 9
Laboratory Corp of America Holdings, Medical Equipment, Deals By Region, 2012 to YTD 2018 10
Laboratory Corp of America Holdings, Deals By Market, 2012 to YTD 2018 11
Laboratory Corp of America Holdings, Medical Equipment, Deals Summary, 2012 to YTD 2018 12
Sequenom Acquires Noninvasive Prenatal Testing Intellectual Property from Isis Innovation for USD14.5 Million 17
Pharma Tech Solutions Acquires Genstrip From Shasta Technologies 19
Sequenom Acquires Molecular Diagnostic Application Patents From Helicos BioSciences For US$1.3 Million 20
Orig3n Raises Funds through Initial Closing of Series B Financing 21
OmniSeq Plans to Raise Funds through Series B Financing 23
Sera Prognostics Raises USD40 Million in Series C Financing 24
Seventh Sense Biosystems Raises USD10 Million in Series C Financing 25
Ativa Medical Raises USD15 Million in Series B Financing 27
Vivify Health Raises Funds in Series B Venture Financing 29
Seventh Sense Biosystems Raises USD16 Million in Series B Financing 30
Flatiron Health Raises US$130 Million In Series B Financing 32
Flatiron Health Raises US$8 Million In Series A Financing 34
Decision Diagnostics Plans to Raise USD4.7 Million in Financing 36
LabCorp Enters into Licensing Agreement with MDNA Life Sciences 37
Sequenom Enters into Licensing Agreement with Mayo Medical Labs 38
Sequenom Enters Into Licensing Agreement With Laboratoire Cerba For MaterniT21 PLUS 39
Ingenuity Systems Enters Into Licensing Agreement With LabCorp For Clinical Content And Applications 41
Sequella Enters Into Licensing Agreement With LabCorp For B-Smart Technology 42
LipoScience Enters Into Licensing Agreement With Cleveland Clinic 43
LabCorp Enters Into Licensing Agreement With OPKO Health For Alzheimer's Diagnostic Technology 44
Covance Enters into Strategic Technology Agreement with GlaxoSmithKline 45
MC10 Enters into Partnership with LabCorp 46
OmniSeq Enters into Distribution Agreement with Laboratory Corp of America 47
Sera Prognostics Enters into Agreement with LabCorp 48
Interpace Diagnostics Extends Agreement with LabCorp 49
Sequenom enters into an Agreement with University of California 50
Sysmex Enters into Co-Development Agreement with LabCorp 51
Cypher Genomics Enters into Agreement with Sequenom to Develop Next Generation Noninvasive Prenatal Tests 52
Gamma-Dynacare Medical Labs Enters Into Agreement With OSR Medical 53
Covance And Pathoquest Enter Into Agreement For Sequencing-Based Biosafety Assessments 54
Enzo Clinical Labs And Sequenom Enter Into Agreement To Market MaterniT21 Plus 55
Sequenom And CombiMatrix Enter Into Agreement To Market Chromosomal Microarray Analysis For Prenatal Testing 56
CombiMatrix Expands Co-Marketing Agreement With Pathology For Prenatal Tests 57
CombiMatrix Enters Into Co-Marketing Agreement With Pathology For Prenatal Tests 58
Mitomics Enters Into Co-Marketing Agreement With LabCorp For Prostate Core Mitomic Test 59
XDx Enters Into Agreement With LabCorp To Develop Lupus Flare Predictor Test 60
MC10 Raises Funds through Private Placement of Shares 61
LipoScience Completes IPO For US$52 Million 62
Sequenom Completes Public Offering Of Common Stock For US$62 Million 64
LabCorp Raises USD600 Million in Public Offering of 3.6% Notes Due 2027 66
LabCorp Raises USD600 Million in Public Offering of 3.25% Notes Due 2024 68
LabCorp Raises USD500 Million in Public Offering of 2.625% Notes Due 2020 70
LabCorp Raises USD1 Billion in Public Offering of 3.6% Notes Due 2025 72
LabCorp Raises USD900 Million in Public Offering of 4.7% Notes Due 2045 74
LabCorp Raises USD500 Million in Public Offering of 3.2% Notes Due 2022 76
LabCorp Completes Public Offering Of Notes Due 2018 For US$400 Million 78
LabCorp Completes Public Offering Of Notes Due 2023 For US$300 Million 80
Sequenom Completes Private Placement Of Notes Due 2017 For US$130 Million 82
LabCorp Completes Public Offering Of Senior Notes Due 2017 For US$500 Million 83
LabCorp Completes Public Offering Of Senior Notes Due 2022 For US$500 Million 85
Sequenom Plans to Sell Clinical Genomic Lab in North Carolina 87
Marken Acquires European Kit Building Operation Facility From LabCorp 88
Eurofins Acquires Covance from LabCorp 89
LabCorp Acquires Sciformix 91
LabCorp Acquires Pathology Associates Medical Labs from Providence Health & Services and Catholic Health Initiatives 92
LabCorp Acquires ClearPath Diagnostics from Shore Capital Partners 94
LabCorp Acquires Sequenom 95
LabCorp Acquires Covance for USD6.1 Billion 97
LabCorp Acquires Bode Technology from SolutionPoint 99
LabCorp Acquires LipoScience for USD85.3 Million 100
Agena Bioscience Completes Acquisition of Sequenom Bioscience for USD31.8 Million 102
Gamma-Dynacare Medical Labs Acquires Controlling Interest In Impact Genetics 103
LabCorp Acquires Minority Stake In SynapDx For US$2 Million 104
LabCorp Completes Acquisition Of Medtox Scientific For US$241 Million 105
Bode Technology Group Acquires Provider Of DNA Analysis Testing Services, Chromosomal Labs 107
Laboratory Corp of America Holdings, Key Competitors 108
Laboratory Corp of America Holdings, Key Employees 109
Laboratory Corp of America Holdings, Other Locations 110
Laboratory Corp of America Holdings, Subsidiaries 111

List of Figures
Laboratory Corp of America Holdings, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
Laboratory Corp of America Holdings, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
Laboratory Corp of America Holdings, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
Laboratory Corp of America Holdings, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
Laboratory Corp of America Holdings, Medical Equipment, Deals By Year, 2012 to YTD 2018 8
Laboratory Corp of America Holdings, Medical Equipment, Deals by Type, 2012 to YTD 2018 9
Laboratory Corp of America Holdings, Medical Equipment, Deals By Region, 2012 to YTD 2018 10
Laboratory Corp of America Holdings, Medical Equipment, Deals by Market, 2012 to YTD 2018 11

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Laboratory Corp of America Holdings (LH):医療機器:M&Aディール及び事業提携情報(Laboratory Corp of America Holdings (LH) - Medical Equipment - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆